These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

457 related items for PubMed ID: 12234992

  • 1. Tirapazamine: a hypoxia-activated topoisomerase II poison.
    Peters KB, Brown JM.
    Cancer Res; 2002 Sep 15; 62(18):5248-53. PubMed ID: 12234992
    [Abstract] [Full Text] [Related]

  • 2. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I, Jensen LH, Jensen PB, Falck J, Rose A, Roerth M, Nitiss JL, Sehested M.
    Cancer Res; 1999 Jul 15; 59(14):3442-50. PubMed ID: 10416608
    [Abstract] [Full Text] [Related]

  • 3. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
    Kusumoto H, Rodgers QE, Boege F, Raimondi SC, Beck WT.
    Cancer Res; 1996 Jun 01; 56(11):2573-83. PubMed ID: 8653700
    [Abstract] [Full Text] [Related]

  • 4. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M, Wessel I, Jensen LH, Holm B, Oliveri RS, Kenwrick S, Creighton AM, Nitiss JL, Jensen PB.
    Cancer Res; 1998 Apr 01; 58(7):1460-8. PubMed ID: 9537249
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of DNA replication by tirapazamine.
    Peters KB, Wang H, Brown JM, Iliakis G.
    Cancer Res; 2001 Jul 15; 61(14):5425-31. PubMed ID: 11454687
    [Abstract] [Full Text] [Related]

  • 6. Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting.
    Delahoussaye YM, Hay MP, Pruijn FB, Denny WA, Brown JM.
    Biochem Pharmacol; 2003 Jun 01; 65(11):1807-15. PubMed ID: 12781332
    [Abstract] [Full Text] [Related]

  • 7. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
    Gieseler F, Bauer E, Nuessler V, Clark M, Valsamas S.
    Leukemia; 1999 Nov 01; 13(11):1859-63. PubMed ID: 10557063
    [Abstract] [Full Text] [Related]

  • 8. Carbonic anhydrase 9 (CA9) expression in tumor cells enhances sensitivity to tirapazamine.
    Shin HJ, Kim JY, Yoo CW, Roberts SA, Lee S, Choi SJ, Lee HY, Lee DH, Kim TH, Cho KH.
    J Cancer Res Clin Oncol; 2008 Mar 01; 134(3):397-404. PubMed ID: 17724612
    [Abstract] [Full Text] [Related]

  • 9. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
    Errington F, Willmore E, Leontiou C, Tilby MJ, Austin CA.
    Cancer Chemother Pharmacol; 2004 Feb 01; 53(2):155-62. PubMed ID: 14504921
    [Abstract] [Full Text] [Related]

  • 10. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.
    Turner JG, Marchion DC, Dawson JL, Emmons MF, Hazlehurst LA, Washausen P, Sullivan DM.
    Cancer Res; 2009 Sep 01; 69(17):6899-905. PubMed ID: 19690141
    [Abstract] [Full Text] [Related]

  • 11. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain.
    Qin Y, Meng L, Hu C, Duan W, Zuo Z, Lin L, Zhang X, Ding J.
    Mol Cancer Ther; 2007 Sep 01; 6(9):2429-40. PubMed ID: 17876042
    [Abstract] [Full Text] [Related]

  • 12. Suppression of hypoxia-inducible factor 1α (HIF-1α) by tirapazamine is dependent on eIF2α phosphorylation rather than the mTORC1/4E-BP1 pathway.
    Zhang J, Cao J, Weng Q, Wu R, Yan Y, Jing H, Zhu H, He Q, Yang B.
    PLoS One; 2010 Nov 09; 5(11):e13910. PubMed ID: 21085474
    [Abstract] [Full Text] [Related]

  • 13. Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines.
    Eijdems EW, de Haas M, Timmerman AJ, Van der Schans GP, Kamst E, de Nooij J, Astaldi Ricotti GC, Borst P, Baas F.
    Br J Cancer; 1995 Jan 09; 71(1):40-7. PubMed ID: 7819046
    [Abstract] [Full Text] [Related]

  • 14. Cytotoxicity of Tirapazamine (3-Amino-1,2,4-benzotriazine-1,4-dioxide)-Induced DNA Damage in Chicken DT40 Cells.
    Moriwaki T, Okamoto S, Sasanuma H, Nagasawa H, Takeda S, Masunaga SI, Tano K.
    Chem Res Toxicol; 2017 Feb 20; 30(2):699-704. PubMed ID: 27943678
    [Abstract] [Full Text] [Related]

  • 15. Assessment of DNA double-strand breaks and gammaH2AX induced by the topoisomerase II poisons etoposide and mitoxantrone.
    Smart DJ, Halicka HD, Schmuck G, Traganos F, Darzynkiewicz Z, Williams GM.
    Mutat Res; 2008 May 10; 641(1-2):43-7. PubMed ID: 18423498
    [Abstract] [Full Text] [Related]

  • 16. Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines.
    Yamazaki K, Isobe H, Hanada T, Betsuyaku T, Hasegawa A, Hizawa N, Ogura S, Kawakami Y.
    Cancer Chemother Pharmacol; 1997 May 10; 39(3):192-8. PubMed ID: 8996519
    [Abstract] [Full Text] [Related]

  • 17. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
    Jensen PB, Sørensen BS, Demant EJ, Sehested M, Jensen PS, Vindeløv L, Hansen HH.
    Cancer Res; 1990 Jun 01; 50(11):3311-6. PubMed ID: 2159380
    [Abstract] [Full Text] [Related]

  • 18. Tirapazamine: a new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer.
    Wouters BG, Wang LH, Brown JM.
    Ann Oncol; 1999 Jun 01; 10 Suppl 5():S29-33. PubMed ID: 10582136
    [Abstract] [Full Text] [Related]

  • 19. Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.
    Aoyama M, Grabowski DR, Dubyak GR, Constantinou AI, Rybicki LA, Bukowski RM, Ganapathi MK, Hickson ID, Ganapathi R.
    Biochem J; 1998 Dec 15; 336 ( Pt 3)(Pt 3):727-33. PubMed ID: 9841887
    [Abstract] [Full Text] [Related]

  • 20. Efficient induction of chromosome-type aberrations by topoisomerase II inhibitors closely associated with stabilization of the cleavable complex in cultured fibroblastic cells.
    Suzuki H, Ikeda T, Yamagishi T, Nakaike S, Nakane S, Ohsawa M.
    Mutat Res; 1995 May 15; 328(2):151-61. PubMed ID: 7739599
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.